KX2-391
Drug timelines are a Plus or Pro feature.
5 regulatory and trial events tracked for KX2-391, covering 2011-03-02 to 2023-02-02. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer [Phase 2]